US-only, turnarounds, contracting, and funding-stale — kept for the record, not the shortlist
updated 2026-07-04 · the demoted half of the employer catalogue
The live catalogue keeps EU-native or genuine-remote-EU employers who are healthy and hiring now. This archive holds everyone who failed one of those three walls: US-only (EU = relocate to the US), turnaround / contracting (walking in the wrong year), or funding-stale / small (verify runway first). Kept for reference — revisit if a specific EU req or a fresh round changes the picture. Back to the shortlist: the live catalogue →
Fit flags: 🔴 skip for this candidate as things stand · 🟡 watch — archived on one wall, but a live req or fresh round could pull it back to the shortlist. Source: bio-data map §4 avoid/caution + the Ginkgo deep-dive (both 2026-07-02).
Real engineering, sometimes even an EU footprint — but the company is cutting, not growing. Hiring here is contraction-hiring.
| Company | Region | Why archived | Fit |
|---|---|---|---|
| Ginkgo Bioworks | 🇺🇸 US (Boston) | The anchor — turnaround-stage, rev −49% YoY (Q1'26), post-1:40 reverse split, ~35% headcount cut. No EU footprint, no visa language, ~15 roles all Boston. Ruby/Python/JS (Rust only in the tiny gen tool). Interesting autonomous-lab scheduling work, but the geo + stack + company-risk walls are decisive. the honest read → | 🔴 skip |
| Recursion | 🇺🇸 US (SLC) + Oxford, UK | Petabyte "Recursion OS" phenomics platform — biggest lab-data flywheel by scale, and it has an Oxford site. But two ~20% cuts, runway-driven consolidation; hiring is contraction. | 🟡 watch |
| Novo Nordisk | 🇪🇺 EU (Bagsværd, DK) | EU-native and would otherwise fit — but ~9,000 jobs cut (11%, ~5k in DK). Deprioritize this year; revisit once the restructure settles. | 🟡 watch |
| Illumina | 🇺🇸 US + Cambridge, UK | ~12% cut over the trailing year, Grail impairment, turnaround/margin mode — not growth-hiring. Aim only if a specific Cambridge-UK DRAGEN req fits. | 🟡 watch |
| Roche / Genentech (US gRED) | 🇺🇸 US (S. SF) | Good data-org thesis, but US gRED in multi-round restructuring (~350+ R&D cuts). Aim Basel/pRED instead — avoid SSF. | 🟡 watch |
Solid companies, some with genuine systems work — but no EU relocation story. "EU" here means moving to the US, not staying in Europe. Skip unless you're open to that move.
| Company | Region | Why archived | Fit |
|---|---|---|---|
| 10x Genomics | 🇺🇸 US (Pleasanton) | The Rust winner — verified production Rust (OSS genomic libs, Go+Rust backend), Cell/Space/Xenium pipelines, stable balance sheet. Archived only on geography: US-only. Worth a US relocation if Rust is the priority. | 🟡 watch |
| TetraScience | 🇺🇸 US (Boston, ~39% remote) | Purest "lab-data-platform-for-AI" peer to Ginkgo Datapoints — instrument connectors + data harmonization. But no EU story, and a 2026 Series-B extension is a momentum caution. | 🟡 watch |
| Insitro | 🇺🇸 US (S. SF) | Automated wet-lab data ↔ ML platform, imaging pipelines, feature stores — strong Datapoints-flavor, systems is first-class. US-only ($700M+ raised). | 🟡 watch |
| Chai Discovery | 🇺🇸 US (SF) | Chai structure-prediction; pure SWE Infrastructure seat, 0→1 scale-ups, OpenAI-backed. US-only. | 🔴 skip |
| Element Biosciences | 🇺🇸 US | US-only, and a TS/React/Electron web-heavy stack — wrong shape for a systems/Rust mind even setting geography aside. | 🔴 skip |
| Ultima Genomics | 🇺🇸 US | Sequencing-instrument data at scale, but US-only, no EU relocation door. | 🔴 skip |
| PacBio | 🇺🇸 US (Menlo Park) | Long-read sequencing platform — US-only. | 🔴 skip |
| Merck | 🇺🇸 US | US-centric and selective visa and a 2028 Keytruda cliff overhang. Three strikes. | 🔴 skip |
| Tempus | 🇺🇸 US (Chicago) | US-only clinical-genomics data. No EU relocation story. | 🔴 skip |
| Guardant Health | 🇺🇸 US (Palo Alto) | US-only liquid-biopsy clinical-genomics. No EU door. | 🔴 skip |
| Freenome | 🇺🇸 US (S. SF) | US-only early-cancer-detection clinical-genomics. No EU door. | 🔴 skip |
| Nucleus | 🇺🇸 US | US-only consumer clinical-genomics. No EU door. | 🔴 skip |
No fresh round in a long time; small headcount. The technology may be interesting but the company-risk is the wall. Confirm a live raise or a real board before spending effort.
| Company | Region | Why archived | Fit |
|---|---|---|---|
| Latch Bio | 🇺🇸 US (SF) | Cloud platform for biology — a robot-lab / lab-OS neighbour with real data-infra, but no fresh round since Series A (Jun 2022). Funding-stale. | 🟡 watch |
| Form Bio | 🇺🇸 US (Dallas) | ~35 employees, $30M Series A (2022), no round since — highest company-risk on the list. | 🔴 skip |
| Color | 🇺🇸 US (Burlingame) | More product than omics-data, mid-pivot, stale 2021 valuation. Wrong shape and shaky footing. | 🔴 skip |